Dural sealant to enter pivotal US trial:
This article was originally published in Clinica
Confluent Surgical is to start a pivotal US study of its dural sealant for preventing cerebrospinal fluid (CSF) leaks, which are associated with neurosurgical and spinal orthopaedic procedures. The FDA has given the Waltham, Massachusetts firm the go-ahead to test its product - DuraSeal - as an adjunct to dural closure in a prospective, multicentre study. As for plans to market the product outside the US, Confluent intends to use results from a recently announced assessment to support an application to CE-mark and launch the product in Europe. The data revealed a 100% intraoperative and 96% post-operative success rate in preventing CSF leak, the company said.
You may also be interested in...
Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.
China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.